O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham | Strategic Alliance Partners

September 30, 2024

Mezigdomide, tazemetostat, and dexamethasone demonstrated early efficacy signals in patients with refractory multiple myeloma.

September 17, 2024

Amitkumar Mehta, MD, discusses FDA-approved treatment options for patients with diffuse large B-cell lymphoma and follicular lymphoma in later lines.

July 30, 2024

akash Desai, MBBS, MPH, discusses unmet needs with the use of chemoimmunotherapy in patients with non–small cell lung cancer.

March 09, 2024

Erica Stringer-Reasor, MD, highlights the evolution of therapies for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

January 29, 2024

Arnab Basu, MD, MPH, FACP, discusses the phase 2 MRD Gate RCC trial of molecular residual disease–guided adjuvant therapy in in renal cell carcinoma.

September 11, 2023

Luciano J. Costa, MD, PhD, discusses clinical implications derived from a final analysis of the phase 2 MASTER trial, which evaluated quadruplet induction therapy in multiple myeloma.

August 25, 2023

Luciano J. Costa, MD, PhD, discussed extended follow-up data from the trial and explained how the results may affect frontline treatment decisions in multiple myeloma.

August 21, 2023

A groundbreaking discovery by Markus Bredel, MD, PhD, and colleagues not only marks a significant milestone in our understanding of diffuse gliomas but also paves the way for improved predictions of disease outcomes and the development of targeted treatment approaches.

August 15, 2023

Francine Walton, MPH, shares how her mother has shaped her perspective on the cancer journey, including the importance of hope and resilience in the face of adversity.

August 11, 2023

The addition of ofranergene obadenovec to paclitaxel failed to significantly improve survival outcomes compared with paclitaxel alone in patients with platinum-resistant ovarian cancer.

August 01, 2023

Luciano J. Costa, MD, PhD, discusses the background of the phase 2 MASTER trial in newly diagnosed multiple myeloma.

July 28, 2023

The University of Alabama at Birmingham, in partnership with the Alabama Department of Public Health and the American Cancer Society, recently launched Wipe Out Cervical Cancer ­— a statewide action plan to eliminate cervical cancer as a public health problem in Alabama.

July 27, 2023

Susan Bal, MD, discusses questions remaining regarding sequencing of treatments in later lines for patients with relapsed/refractory multiple myeloma.

July 24, 2023

The O’Neal Comprehensive Cancer Center at UAB is pleased to announce that Rebecca Arend, M.D., MSPH, will join Drs. Narendra Wajapeyee and Suzanne Lapi as Co-Leader of the O’Neal Experimental Therapeutics Research Program.

July 19, 2023

Ahmed Elkhanany, MD discusses unmet needs in patients with estrogen receptor–positive breast cancer who progress on frontline therapy, treatment considerations for these patients, and how FES PET imaging may benefit this population.

June 22, 2023

Susan Bal, MD, discusses the toxicity profile of the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in relapsed/refractory multiple myeloma, according to findings from a phase 1 trial.

June 21, 2023

Susan Bal, MD, discusses updated safety and efficacy data from the dose-escalation and dose-expansion portions of phase 1 trial of the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in patients with relapsed/refractory multiple myeloma.

June 21, 2023

Luciano J. Costa, MD, PhD, discusses data on the use of minimal residual disease responses to modulate quadruplet induction therapy following autologous stem cell transplant in newly diagnosed multiple myeloma.

June 15, 2023

Ahmed Elkhanany, MD, discusses biological drivers of disease in patients with estrogen receptor–positive breast cancer who have disease progression shortly after initiating first-line therapy, as well as the importance of performing comprehensive genetic testing in these patients to determine subsequent treatment approaches. 

May 26, 2023

Susan Bal, MD, discusses the data that supported the FDA approvals of ide-cel and cilta-cel, how the implementation of these agents has shifted how patients with later-line relapsed/refractory multiple myeloma are treated, and the challenges that still need to be addressed with CAR T-cell therapy.